Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
复制标题
竞争性 CBFbeta/MYH11 逆转录酶聚合酶链反应用于定量评估反转急性髓系白血病缓解后治疗期间的微小残留病(16)：一项试点研究。
DOI：
10.1200/jco.1998.16.4.1519
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
U. Jaeger
中科院分区：
文献类型：
--
作者：
K. Laczika;M. Novak;B. Hilgarth;M. Mitterbauer;G. Mitterbauer;A. Scheidel;C. Scholten;R. Thalhammer;S. Brugger;F. Keil;I. Schwarzinger;O. Haas;Klaus Lechner;U. Jaeger
目的
(1)通过竞争性CBFbeta/MYH 11逆转录酶聚合酶链反应（RT-PCR）定量急性髓性白血病（AML）和倒位患者缓解后治疗期间的微小残留病（MRD）（16）[inv（16）]，（2）该方法与传统两步RT-PCR的比较，（3）潜在预后价值的评价。
患者和方法
连续6例成人AML患者的MRD和inv（16）（p13;q22）或t（16;16）（p13; q22）进入完全缓解（CR）的患者，在缓解后使用高剂量阿糖胞苷（HiDAC）治疗期间或使用匹配的无关供体骨髓（MUD-BMT）进行骨髓移植后，通过竞争性CBFbeta/MYH 11 RT-PCR对其骨髓（BM）进行监测。在开始治疗后4.5至27个月的观察期内。
结果
竞争性PCR显示，连续CR（CCR）患者在7至9个月后逐渐下降至少4个数量级，而1例13.5个月后复发的患者在巩固治疗结束时仅下降2个数量级。MUD-BMT后2例患者在1个月内观察到低于检测限的快速下降。在移植物抗宿主病（GvHD）的免疫抑制期间，在这些患者中观察到分子MRD的暂时重现。在减少免疫抑制后，MRD水平再次降至PCR检测限以下。传统的两步RT-PCR的分子监测只有在每个时间点进行多个检测时才能产生可比的结果，而单次检测RT-PCR则会产生误导性结果。
结论
竞争性RT-PCR是缓解后化疗以及骨髓移植后分子监测的一种有价值的工具。
PURPOSE
(1) Quantification of minimal residual disease (MRD) by competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction (RT-PCR) in patients with acute myeloid leukemia (AML) and inversion(16) [inv(16)] during postremission therapy, (2) comparison of this method with conventional two-step RT-PCR, and (3) evaluation of a potential prognostic value.
PATIENTS AND METHODS
MRD of six consecutive adult patients with AML and inv(16)(p13;q22) or t(16;16)(p13;q22) who entered complete remission (CR) was monitored by competitive CBFbeta/MYH11 RT-PCR in their bone marrow (BM) during postremission therapy with high-dose cytarabine (HiDAC) or after BM transplantation with a matched unrelated-donor marrow (MUD-BMT) during an observation period of 4.5 to 27 months after initiation of treatment.
RESULTS
Competitive PCR showed a gradual decline by at least 4 orders of magnitude after 7 to 9 months in patients in continuous CR (CCR), while one patient who relapsed after 13.5 months only achieved a reduction by 2 orders of magnitude at the end of consolidation therapy. A rapid decrease below the detection limit was observed within 1 month in two patients after MUD-BMT. A temporary reappearance of molecular MRD was observed in these patients during immunosuppression for graft-versus-host disease (GvHD). After reduction of immunosuppression, the level of MRD dropped again below the PCR detection limit. Molecular monitoring by conventional two-step RT-PCR yielded comparable results only when multiple assays per time point were performed, while single-assay RT-PCR gave misleading results.
CONCLUSION
Competitive RT-PCR is a valuable tool for molecular monitoring during postremission chemotherapy, as well as after BMT.
登录
查看更多内容
影响因子：
158.5
作者：
MAYER, RJ;DAVIS, RB;FREI, E
通讯作者：
FREI, E
DOI：
10.1016/j.hemonc.2016.08.005
发表时间：
2017-03-01
期刊：
Hematology/oncology and stem cell therapy
影响因子：
--
作者：
Ayatollahi, Hossein;Shajiei, Arezoo;Shakeri, Sepideh
通讯作者：
Shakeri, Sepideh
持续输注大剂量阿糖胞苷治疗新诊断的急性髓性白血病的长期结果。
影响因子：
11.4
作者：
Ghaddar,HM;Plunkett,W;Kantarjian,HM;Pierce,S;Freireich,EJ;Keating,MJ;Estey,EH
通讯作者：
Estey,EH
急性髓系白血病中 inv(16)(p13q22) 和 t(16;16)(p13;q22) 编码的 CBF beta/MYH11 融合信息的异质性。
影响因子：
20.3
作者：
Shurtleff,SA;Meyers,S;Hiebert,SW;Raimondi,SC;Head,DR;Willman,CL;Wolman,S;Slovak,ML;Carroll,AJ;Behm,F
通讯作者：
Behm,F